HIV-1 Drug Resistance in Different Subtypes
不同亚型的 HIV-1 耐药性
基本信息
- 批准号:8139079
- 负责人:
- 金额:$ 81.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAffectAfricaAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral resistanceAsiaBiological AssayCaringChinaClinical DataCodon NucleotidesCollaborationsCountryDataDatabasesDiagnostic testsDrug ExposureDrug resistanceEffectivenessEmergency SituationEpidemicEuropeEvolutionFailureFrequenciesGenbankGeneticGenetic PolymorphismGenotypeGoalsHIVHIV drug resistanceHIV-1IncidenceIndiaIndividualInfectionInternationalKnowledgeLifeLinkLiteratureMethodsMonitorMutationPatientsPatternPeptide HydrolasesPersonsPharmaceutical PreparationsPhylogenetic AnalysisPlasmaPopulationPositioning AttributePredispositionPrevalencePrincipal InvestigatorProtocols documentationPublic HealthPublishingRNA-Directed DNA PolymeraseRecombinantsRegimenResearchResearch InfrastructureResistanceResourcesSamplingScienceSensitivity and SpecificityShippingShipsSpecimenSurveillance ProgramTestingThailandTreatment FailureTreatment ProtocolsValidationVariantVertebral columnViral GenesViremiaVirusWorkantiretroviral therapybasecohortcostdesignexperiencenovelpandemic diseasepopulation basedprogramspublic health relevancerecombinant virusresistance mutationresponsescale upstemtransmission processtreatment centertreatment programtreatment strategyworking group
项目摘要
DESCRIPTION (provided by applicant): The human immunodeficiency virus (HIV-1) pandemic is due to multiple subtypes and emerging recombinant viruses that are widely distributed around the world. An important response to the epidemic is the global scale-up of access to antiretroviral treatment (ART) programs, potentially delivering ART to millions of infected individuals. A barrier to successful long term treatment is the emergence of drug resistance, caused by mutations selected in viral genes, which are both a cause and a consequence of ART failure. Knowledge about drug resistance comes largely from the US and Europe, focused on one HIV-1 variant, subtype B. However, 90% of infections globally, are in resource limited settings in Africa and Asia, where other distinct, non-B HIV-1 subtypes predominate. There is strong preliminary evidence that pre-therapy genotypes differ among subtypes and that distinct mutations at positions related to resistance may occur, even before treatment, among non-B subtypes. Furthermore, distinct, new mutations are detected in non-B subtypes after drug-exposure. Information on susceptibility and resistance of non-B viruses is critical for strategies to sustain the benefit of ART. Prevalence and incidence of transmitted and acquired drug resistance will drive decisions about diagnostic testing, initial and second-line therapies in public health HIV treatment programs in resource limited settings. The focus of this proposal is to build the scientific infrastructure for surveillance and monitoring of drug resistance in three Resource-limited settings, where specific non- B subtypes predominate. Through these studies we will develop a robust sequence database of HIV-1 non-B variants for genotypic analyses and phenotypic validation of resistance mutations and patterns. We have designed a program to first develop quality assured, low cost drug resistance monitoring strategies using dried filter specimens for resistance testing. These strategies will be implemented in Thailand, India and china, to study differences between HIV-1 subtypes in drug resistance to current first-line, WHO- recommended treatment regimens. In collaboration with Monogram Biosciences we will assess the importance of mutations and patterns in these samples using an advanced method for phenotypic resistance testing. The goals of this proposal are to (i) validate low-cost resistance testing; (ii) determine frequency and patterns of virological failure and drug resistance after 1 and 2 years of ART; and (iii) conduct genotypic analyses and phenotypic validation of subtype-specific mutations and patterns.
PUBLIC HEALTH RELEVANCE: The HIV-1 pandemic is a global emergency caused by multiple subtypes. Evolution of anti-HIV drug resistance is the main cause and consequence of drug treatment failure. Most knowledge about drug resistance stems from work in the US and Europe on the relatively uncommon subtype B HIV-1. In resource limited settings, where the majority of the pandemic prevails, non-B subtypes and circulating recombinant forms (CRF) predominate. Treatment access programs are rapidly increasing the numbers of AIDS patients, throughout the world, who are receiving combinations of antiretroviral therapies (ART). Our long-term goal is to determine the how different subtypes of HIV-1 respond to treatment with antiretroviral drugs and the significance of subtype in the selection and the evolution of drug resistance.
描述(由申请人提供):人类免疫缺陷病毒(HIV-1)大流行是由多种亚型和新出现的重组病毒引起的,它们广泛分布在世界各地。应对这一流行病的一项重要措施是在全球范围内扩大抗逆转录病毒治疗方案的可及性,可能为数百万感染者提供抗逆转录病毒治疗。长期治疗成功的一个障碍是耐药性的出现,耐药性是由病毒基因中选择的突变引起的,这既是抗逆转录病毒治疗失败的原因,也是其后果。关于耐药性的知识主要来自美国和欧洲,主要集中在一种HIV-1亚型b。然而,全球90%的感染发生在非洲和亚洲资源有限的环境中,在那里其他不同的非b型HIV-1亚型占主导地位。有强有力的初步证据表明,治疗前不同亚型的基因型不同,甚至在治疗前,在非b亚型中,与耐药性相关的位置可能发生明显的突变。此外,在药物暴露后,在非b亚型中检测到明显的新突变。关于非b型病毒的易感性和耐药性的信息对于维持抗逆转录病毒治疗的益处的战略至关重要。在资源有限的环境下,传播性和获得性耐药性的流行程度和发生率将推动公共卫生艾滋病毒治疗方案中关于诊断测试、初始和二线治疗的决定。本建议的重点是在三个资源有限的环境中建立监测和监测耐药性的科学基础设施,这些环境中特定的非B亚型占主导地位。通过这些研究,我们将开发一个强大的HIV-1非b变异体序列数据库,用于抗性突变和模式的基因型分析和表型验证。我们设计了一个方案,首先开发质量有保证、低成本的耐药性监测策略,使用干燥的过滤标本进行耐药性测试。这些战略将在泰国、印度和中国实施,以研究HIV-1亚型对目前世卫组织推荐的一线治疗方案的耐药性差异。与Monogram Biosciences合作,我们将使用一种先进的表型抗性测试方法来评估这些样本中突变和模式的重要性。本提案的目标是:(i)验证低成本的耐药性测试;确定1年和2年抗逆转录病毒治疗后病毒学失败和耐药性的频率和模式;(iii)对亚型特异性突变和模式进行基因型分析和表型验证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rami Kantor其他文献
Rami Kantor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rami Kantor', 18)}}的其他基金
Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents
解决一群围产期感染的肯尼亚儿童和青少年的艾滋病毒耐药性研究空白
- 批准号:
10630333 - 财政年份:2019
- 资助金额:
$ 81.14万 - 项目类别:
HIV Treatment Failure and Drug Resistance in Western Kenyan Children
肯尼亚西部儿童的艾滋病毒治疗失败和耐药性
- 批准号:
9925893 - 财政年份:2019
- 资助金额:
$ 81.14万 - 项目类别:
Real Time Phylogeny and Contact Tracing to Disrupt HIV Transmission
实时系统发育和接触者追踪以阻断艾滋病毒传播
- 批准号:
10335147 - 财政年份:2018
- 资助金额:
$ 81.14万 - 项目类别:
Real Time Phylogeny and Contact Tracing to Disrupt HIV Transmission
实时系统发育和接触者追踪以阻断艾滋病毒传播
- 批准号:
10097973 - 财政年份:2018
- 资助金额:
$ 81.14万 - 项目类别:
HIV Treatment Failure and Drug Resistance in Western Kenyan Children
肯尼亚西部儿童的艾滋病毒治疗失败和耐药性
- 批准号:
9147181 - 财政年份:2016
- 资助金额:
$ 81.14万 - 项目类别:
HIV Treatment Failure and Drug Resistance in Western Kenyan Children
肯尼亚西部儿童的艾滋病毒治疗失败和耐药性
- 批准号:
9324832 - 财政年份:2016
- 资助金额:
$ 81.14万 - 项目类别:
HIV Drug Resistance Monitoring in Chennai, India
印度钦奈的艾滋病毒耐药性监测
- 批准号:
8709987 - 财政年份:2013
- 资助金额:
$ 81.14万 - 项目类别:
HIV Drug Resistance Monitoring in Chennai, India
印度钦奈的艾滋病毒耐药性监测
- 批准号:
8540028 - 财政年份:2013
- 资助金额:
$ 81.14万 - 项目类别:
Antiretroviral Treatment Failure and Drug Resistance in HIV-infected Patients on
HIV感染者的抗逆转录病毒治疗失败和耐药性
- 批准号:
8150159 - 财政年份:2010
- 资助金额:
$ 81.14万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 81.14万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 81.14万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 81.14万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 81.14万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 81.14万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 81.14万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 81.14万 - 项目类别: